<DOC>
	<DOCNO>NCT00844714</DOCNO>
	<brief_summary>The purpose investigation determine effect Rituxan therapy individual rheumatoid arthritis endothelial function marker endothelial function</brief_summary>
	<brief_title>Cardiovascular Risk Markers Patients With Rheumatoid Arthritis : Effect Rituximab Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Able willing give write informed consent comply requirement study protocol Negative serum pregnancy test ( woman child bear age ) Men woman reproductive potential must agree use acceptable method birth control treatment twelve month ( 1 year ) completion treatment . IgG &amp; IgM level within normal limit Adequate renal function indicate serum creatinine measurement . No previous biological use ( investigational approve ) except three approve antiTNF alpha therapy Patients treat antiTNF alpha therapy must infliximab adalimumab two month study entry etanercept one month study entry No use phosphodiesterase type 5 inhibitor ( PDE5 ) ( i.e . Sildenafil , Tadalafil , Vardenafil ) 1 week prior study course study . SBP â‰¤ 140/90 two month prior study enrollment Prior history MI , CVA , CABG , PTCA , peripheral vascular disease Any serious concomitant medical condition could interfere study . Patients insulin dependent diabetes Failure provide write consent . Individuals HIV infection SBP &gt; 140/90 two month prior study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>endothelial function</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>cardiovascular risk</keyword>
	<keyword>rituxan therapy</keyword>
</DOC>